| Datum | Zeit | Quelle | Überschrift | Symbol | Firma |
| 03/01/2012 | 14h00 | Marketwired | Poniard Pharmaceuticals Common Stock to Be Delisted From Nasdaq Stock Market, Intention to List on OTC Bulletin Board | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 23/12/2011 | 21h37 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 22/11/2011 | 20h13 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 21/11/2011 | 19h15 | Marketwired | Poniard Pharmaceuticals Announces Shareholders Approve Merger With ALLOZYNE | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 21/11/2011 | 15h00 | Marketwired | Steps in the Right Direction - Featured Research on Poniard Pharmaceuticals, Inc. and Gilead Sciences, Inc. | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 18/11/2011 | 19h00 | Edgar (US Regulatory) | Filing of certain prospectuses and communications in connection with business combination transactions (425) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 18/11/2011 | 14h30 | Marketwired | Poniard Pharmaceuticals Announces Licensing Agreement for Focal Adhesion Kinase Technology | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 10/11/2011 | 20h54 | Edgar (US Regulatory) | Filing of certain prospectuses and communications in connection with business combination transactions (425) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 09/11/2011 | 19h16 | Edgar (US Regulatory) | Filing of certain prospectuses and communications in connection with business combination transactions (425) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 09/11/2011 | 14h30 | Marketwired | ISS Proxy Advisory Services Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse St... | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 08/11/2011 | 12h05 | Edgar (US Regulatory) | Filing of certain prospectuses and communications in connection with business combination transactions (425) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 07/11/2011 | 14h30 | Marketwired | Glass Lewis Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse Stock Split | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 04/11/2011 | 11h10 | Edgar (US Regulatory) | Prospectus filed pursuant to Rule 424(b)(3) (424B3) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 02/11/2011 | 21h01 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 28/10/2011 | 22h16 | Edgar (US Regulatory) | Filing of certain prospectuses and communications in connection with business combination transactions (425) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 28/10/2011 | 22h01 | Marketwired | Poniard Pharmaceuticals Reports Third Quarter 2011 Financial Results | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 28/10/2011 | 19h59 | Edgar (US Regulatory) | Quarterly Report (10-Q) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 28/10/2011 | 17h19 | Edgar (US Regulatory) | Filing of certain prospectuses and communications in connection with business combination transactions (425) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 28/10/2011 | 14h30 | Marketwired | Egan-Jones Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse Stock Split | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 24/10/2011 | 21h47 | Edgar (US Regulatory) | Filing of certain prospectuses and communications in connection with business combination transactions (425) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 21/10/2011 | 20h00 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (DEFA14A) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 12/10/2011 | 19h43 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 12/10/2011 | 19h41 | Edgar (US Regulatory) | Filing of certain prospectuses and communications in connection with business combination transactions (425) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 12/10/2011 | 19h37 | Edgar (US Regulatory) | Prospectus filed pursuant to Rule 424(b)(3) (424B3) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 11/10/2011 | 15h10 | Dow Jones News | Registration Effectiveness Orders Issued By The SEC | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 11/10/2011 | 12h00 | Edgar (US Regulatory) | Notice of Effectiveness (EFFECT) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 07/10/2011 | 23h43 | Marketwired | Poniard Pharmaceuticals Announces Effectiveness of Form S-4 Registration Statement for the Proposed Merger with ALLOZYNE | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 07/10/2011 | 23h27 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 07/10/2011 | 23h26 | Edgar (US Regulatory) | Filing of certain prospectuses and communications in connection with business combination transactions (425) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |
| 07/10/2011 | 19h22 | Edgar (US Regulatory) | Confidential Treatment Order (CT ORDER) | NASDAQ:PARD | Poniard Pharmaceuticals, Inc. (MM) |